TABLE 2.
Open in new tab

Baseline Characteristics of Vedolizumab Response Cohort

Responders (N = 38)Nonresponders (N = 26)PTotal (N = 64)
Mean age, years ± SD46 ± 1542 ± 130.2344 ± 14
Female sex, N (%)18 (47)13 (50)0.8433 (52)
Race/Ethnicity, N (%)0.06
 White32 (84)19 (73)51 (80)
 Hispanic2 (5)0 (0)2 (3)
 African American0 (0)3 (12)3 (5)
 Asian0 (0)2 (8)2 (3)
 Other4 (11)2 (8)6 (9)
Average BMI ± SD, kg/m226.9 ± 7.525.8 ± 5.40.4926.5 ± 6.7
Disease phenotype, N (%)
 Fistulizing9 (24)8 (31)0.5317 (27)
 Fibrostenotic7 (18)7 (27)0.4214 (22)
Disease Location, N (%)0.41
 Ileum only12 (32)5 (19)17 (27)
 Colon only5 (13)6 (23)11 (17)
 Ileum and colon21 (55)15 (58)36 (56)
Concomitant Medication Use, N (%)
 Immunomodulator28 (74)20 (77)0.7748 (75)
 Corticosteriods28 (74)18 (69)0.7046 (72)
Prior anti-TNF exposure32 (84)24 (92)0.3456 (88)
Responders (N = 38)Nonresponders (N = 26)PTotal (N = 64)
Mean age, years ± SD46 ± 1542 ± 130.2344 ± 14
Female sex, N (%)18 (47)13 (50)0.8433 (52)
Race/Ethnicity, N (%)0.06
 White32 (84)19 (73)51 (80)
 Hispanic2 (5)0 (0)2 (3)
 African American0 (0)3 (12)3 (5)
 Asian0 (0)2 (8)2 (3)
 Other4 (11)2 (8)6 (9)
Average BMI ± SD, kg/m226.9 ± 7.525.8 ± 5.40.4926.5 ± 6.7
Disease phenotype, N (%)
 Fistulizing9 (24)8 (31)0.5317 (27)
 Fibrostenotic7 (18)7 (27)0.4214 (22)
Disease Location, N (%)0.41
 Ileum only12 (32)5 (19)17 (27)
 Colon only5 (13)6 (23)11 (17)
 Ileum and colon21 (55)15 (58)36 (56)
Concomitant Medication Use, N (%)
 Immunomodulator28 (74)20 (77)0.7748 (75)
 Corticosteriods28 (74)18 (69)0.7046 (72)
Prior anti-TNF exposure32 (84)24 (92)0.3456 (88)
TABLE 2.
Open in new tab

Baseline Characteristics of Vedolizumab Response Cohort

Responders (N = 38)Nonresponders (N = 26)PTotal (N = 64)
Mean age, years ± SD46 ± 1542 ± 130.2344 ± 14
Female sex, N (%)18 (47)13 (50)0.8433 (52)
Race/Ethnicity, N (%)0.06
 White32 (84)19 (73)51 (80)
 Hispanic2 (5)0 (0)2 (3)
 African American0 (0)3 (12)3 (5)
 Asian0 (0)2 (8)2 (3)
 Other4 (11)2 (8)6 (9)
Average BMI ± SD, kg/m226.9 ± 7.525.8 ± 5.40.4926.5 ± 6.7
Disease phenotype, N (%)
 Fistulizing9 (24)8 (31)0.5317 (27)
 Fibrostenotic7 (18)7 (27)0.4214 (22)
Disease Location, N (%)0.41
 Ileum only12 (32)5 (19)17 (27)
 Colon only5 (13)6 (23)11 (17)
 Ileum and colon21 (55)15 (58)36 (56)
Concomitant Medication Use, N (%)
 Immunomodulator28 (74)20 (77)0.7748 (75)
 Corticosteriods28 (74)18 (69)0.7046 (72)
Prior anti-TNF exposure32 (84)24 (92)0.3456 (88)
Responders (N = 38)Nonresponders (N = 26)PTotal (N = 64)
Mean age, years ± SD46 ± 1542 ± 130.2344 ± 14
Female sex, N (%)18 (47)13 (50)0.8433 (52)
Race/Ethnicity, N (%)0.06
 White32 (84)19 (73)51 (80)
 Hispanic2 (5)0 (0)2 (3)
 African American0 (0)3 (12)3 (5)
 Asian0 (0)2 (8)2 (3)
 Other4 (11)2 (8)6 (9)
Average BMI ± SD, kg/m226.9 ± 7.525.8 ± 5.40.4926.5 ± 6.7
Disease phenotype, N (%)
 Fistulizing9 (24)8 (31)0.5317 (27)
 Fibrostenotic7 (18)7 (27)0.4214 (22)
Disease Location, N (%)0.41
 Ileum only12 (32)5 (19)17 (27)
 Colon only5 (13)6 (23)11 (17)
 Ileum and colon21 (55)15 (58)36 (56)
Concomitant Medication Use, N (%)
 Immunomodulator28 (74)20 (77)0.7748 (75)
 Corticosteriods28 (74)18 (69)0.7046 (72)
Prior anti-TNF exposure32 (84)24 (92)0.3456 (88)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close